---
title: "According to reports, Eli Lilly plans to acquire Ventyx Biosciences for over $1 billion"
description: "Eli Lilly is in talks to acquire Ventyx Biosciences for over $1 billion, according to The Wall Street Journal. This deal could expand Eli Lilly's product line to include drugs for the treatment of inf"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/271704188.md"
published_at: "2026-01-06T21:47:02.000Z"
---

# According to reports, Eli Lilly plans to acquire Ventyx Biosciences for over $1 billion

> Eli Lilly is in talks to acquire Ventyx Biosciences for over $1 billion, according to The Wall Street Journal. This deal could expand Eli Lilly's product line to include drugs for the treatment of inflammatory bowel disease and Parkinson's disease. One of Ventyx's experimental drugs is also in mid-stage development aimed at treating obesity-related cardiovascular diseases. Ventyx's stock price rose more than 50% in after-hours trading

The Wall Street Journal reported on Tuesday that Eli Lilly (LLY.US) is in advanced negotiations to acquire Ventyx Biosciences (VTYX.US) for over $1 billion. Ventyx's stock price surged more than 50% in after-hours trading.

The potential acquisition of Ventyx would add drugs for the treatment of inflammatory bowel disease and drugs for diseases such as Parkinson's to Eli Lilly's product pipeline. Additionally, one of Ventyx's experimental drugs is currently in mid-stage development for the treatment of obesity-related cardiovascular diseases

### Related Stocks

- [VTYX.US - Ventyx Biosciences](https://longbridge.com/en/quote/VTYX.US.md)
- [LLY.US - Eli Lilly](https://longbridge.com/en/quote/LLY.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Eli Lilly (LLY) Builds $1.5 Billion Inventory of Weight-Loss Pill | Eli Lilly (LLY) has prepared a $1.5 billion inventory of its new weight-loss pill, Orforglipron, ahead of its anticipate | [Link](https://longbridge.com/en/news/276070062.md) |
| Eli Lilly and Company $LLY Shares Acquired by Assetmark Inc. | Assetmark Inc. increased its holdings in Eli Lilly and Company (NYSE: LLY) by 6.0% in Q3, owning 55,360 shares valued at | [Link](https://longbridge.com/en/news/275971336.md) |
| Eli Lilly: Mirikizumab approved in China for treatment of moderate-to-severe Crohn's disease and ulcerative colitis - Co statement | Eli Lilly: Mirikizumab approved in China for treatment of moderate-to-severe Crohn's disease and ulcerative colitis - Co | [Link](https://longbridge.com/en/news/275551012.md) |
| Short Interest in Schneider Electric SE (OTCMKTS:SBGSY) Drops By 16.8% | Schneider Electric SE (OTCMKTS:SBGSY) experienced a 16.8% decrease in short interest in January, with 197,858 shares sho | [Link](https://longbridge.com/en/news/276071356.md) |
| CICC Reaffirms Their Buy Rating on NIO Inc. Class A (9866) | CICC analyst maintained a Buy rating on NIO Inc. Class A yesterday and set a price target of HK$50.00.Valentine's Day Sa | [Link](https://longbridge.com/en/news/275967598.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
